Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
MENLO PARK, Calif., April 05, 2016 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2016 Financial Results on Thursday, April 21, 2016, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: April 21, 2016
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
